HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy. Klc TR, Wu S, Wilhite AM, Jones NL, et al. Gynecol Oncol 2022 Sep 13. pii: S0090-8258(22)00592.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Klc TR, Wu S, Wilhite AM, Jones NL, et al. HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy. Gynecol Oncol 2022 Sep 13. pii: S0090-8258(22)00592.
PMID: 36114027